Abstract:
The present application relates to solid state forms, for example, crystalline forms of 2'- C-methyluridine-5 '-(O-phenyl-N-(S)- 1 -(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2'-C-methyluridine-5'- (0-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2'-C-methyluridine-5'- (O-phenyl-N-(S)- 1 -(isopropoxy carbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2'-C- methyluridine-5 '-(O-phenyl-N-(S)- 1 -(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
Abstract:
The present disclosure relates to co-crystals comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits.
Abstract:
Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).
Abstract:
La descripción proporciona al menos un compuesto, tautómero, derivado deuterado, o sal farmacéuticamente aceptable elegida de compuestos de Fórmula (I), tautómeros de estos, derivados deuterados de esos compuestos o tautómeros, y sales farmacéuticamente aceptables de cualquiera de los anteriores, composiciones que comprenden los mismos, y métodos de uso de los mismos, incluidos los usos en el tratamiento de enfermedades mediadas por APOL1, incluido el cáncer pancreático, la glomeruloesclerosis segmentaria focal (FSGS), y/o la enfermedad renal no diabética (NDKD).
Abstract:
La descripción proporciona al menos un compuesto, tautómero, derivado deuterado, o sal farmacéuticamente aceptable elegida de compuestos de Fórmula (I), tautómeros de estos, derivados deuterados de esos compuestos o tautómeros, y sales farmacéuticamente aceptables de cualquiera de los anteriores, composiciones que comprenden los mismos, y métodos de uso de los mismos, incluidos los usos en el tratamiento de enfermedades mediadas por APOL1, incluido el cáncer pancreático, la glomeruloesclerosis segmentaria focal (FSGS), y/o la enfermedad renal no diabética (NDKD). (ver Fórmula).
Abstract:
The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula (I), tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
Abstract:
Se describen formas cristalinas del Compuesto I: I, sales farmacéuticamente aceptables de este, y solvatos e hidratos de estas. También se describen composiciones farmacéuticas que comprenden las mismas, métodos para tratar la fibrosis quística mediante el uso de las mismas y métodos para fabricar las mismas.
Abstract:
The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I), tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.